Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript
07:32pm, Thursday, 19'th Mar 2026
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
08:00am, Thursday, 19'th Mar 2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – �
Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference
02:02am, Monday, 16'th Mar 2026
Collegium Pharmaceutical (NASDAQ: COLL) highlighted a "record-breaking" 2025 and outlined its 2026 outlook at the Barclays Miami Conference, emphasizing strong performance from newly acquired ADHD pro
Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
11:52am, Wednesday, 11'th Mar 2026
Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Collegium to Present New Real-World Data at PainConnect 2026
08:00am, Thursday, 05'th Mar 2026
STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of different
Collegium to Participate in Upcoming Investor Conferences
08:00am, Monday, 02'nd Mar 2026
STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Leerink
Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
05:37pm, Thursday, 26'th Feb 2026
Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say
01:30pm, Thursday, 26'th Feb 2026
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compa
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates
01:16pm, Thursday, 26'th Feb 2026
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $2.04 per share, missing the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $1.77 per share a year ago.
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
07:30am, Thursday, 26'th Feb 2026
– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year –
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:01am, Thursday, 19'th Feb 2026
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Crosses Below 50 Day Moving Average – Here’s What Happened
04:22am, Wednesday, 18'th Feb 2026
Collegium Pharmaceutical, Inc. (NASDAQ: COLL - Get Free Report) crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $47.17 and traded as l
Analyzing Collegium Pharmaceutical (NASDAQ:COLL) and Pivotal Therapeutics (OTCMKTS:PVTTF)
03:13am, Wednesday, 28'th Jan 2026
Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Pivotal Therapeutics (OTCMKTS:PVTTF - Get Free Report) are both medical companies, but which is the superior business? We will contrast th
Collegium Pharmaceutical, Inc. $COLL Shares Sold by Emerald Advisers LLC
04:53am, Thursday, 22'nd Jan 2026
Emerald Advisers LLC reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 23.6% during the undefined quarter, according to the company in its most recent filing with the Sec
Collegium Pharmaceutical: Buying The Projected Growth For 2026
10:45pm, Wednesday, 21'st Jan 2026
Collegium Pharmaceutical demonstrates strong profitability, upgraded 2026 guidance, and a robust balance sheet, reinforcing my bullish outlook and conviction upgrade. COLL's growth is shifting from Xt
